Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.78 |
| ▸ | PGRMC1 | O00264 | 1/20 | 0.56 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | CDK4 | P11802 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | CCKBR | P32239 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.56 |
| ▸ | PCYT1A | P49585 | 1/20 | 0.56 |
| ▸ | GSK3A | P49840 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.56 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.56 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16105880 | 1.00 | BRAF (0.78) | BRAFPGRMC1RIPK2NR1I2CDK4 | |
| SCHEMBL12094308 | 0.93 | BRAF (0.90) | BRAFPGRMC1RIPK2NR1I2CDK4 | |
| SCHEMBL1494674 | 0.93 | BRAF (0.79) | BRAF | |
| SCHEMBL16105847 | 0.93 | BRAF (0.79) | BRAF | |
| SCHEMBL16105935 | 0.89 | BRAF (0.69) | BRAFPGRMC1RIPK2NR1I2CDK4 | |
| SCHEMBL11982677 | 0.87 | BRAF (0.90) | BRAF | |
| SCHEMBL6522901 | 0.87 | BRAF (0.78) | BRAF | |
| SCHEMBL16105850 | 0.83 | BRAF (0.68) | BRAF | |
| SCHEMBL1494721 | 0.82 | BRAF (0.78) | BRAF | |
| SCHEMBL16105852 | 0.82 | BRAF (0.78) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470528-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-10-01 | — | — | EP | claimed |
| US-8563553-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | claimed |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-09-06 | — | — | US | claimed |
| US-8242260-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | claimed |
| EP-2470528-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | claimed |
| WO-2011023773-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | claimed |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-03 | — | — | US | claimed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-4719606-A2 | GCN2 AND PERK KINASE MODULATORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12577249-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2026-03-17 | — | — | US | disclosed |
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC | 2025-10-02 | — | — | US | disclosed |
| US-20250206747-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2025-06-26 | — | — | US | disclosed |
| US-20130296318-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8563553-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| US-8501758-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-08-06 | — | — | US | disclosed |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-09-06 | — | — | US | disclosed |
| US-8242260-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-15 | — | — | US | disclosed |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885PGRMC1 3549/4885RIPK2 384/4885 |
| US-12577249-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | BRAF 58/4885PGRMC1 2360/4885RIPK2 500/4885 |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | BRAF 2/4885PGRMC1 2984/4885RIPK2 169/4885 |
| US-20130296318-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885PGRMC1 3549/4885RIPK2 384/4885 |
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | BRAF 2779/4885PGRMC1 1830/4885RIPK2 2653/4885 |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | PTPN1, PTPN2, PTPN18 | BRAF 116/4885PGRMC1 3833/4885RIPK2 275/4885 |
| US-20250206747-A1 | COELENTERAZINE ANALOGUES | GLB1, AADAC, SI | BRAF 3993/4885PGRMC1 4834/4885RIPK2 3242/4885 |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | BRAF 2/4885PGRMC1 2984/4885RIPK2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.